Posted 21st October 2024
Posted 8 months ago
By Pfizer
Pfizer Shares Patient Letter re Voxelotor (Oxybryta®) Withdrawal
Pfizer Shares Patient Advice Regarding Immediate Withdrawal of Voxelotor (Oxybryta®)
Pfizer Shares Patient Advice Regarding Immediate Withdrawal of Voxelotor (Oxybryta®)
Following the unforeseen Pfizer withdrawal of Voxelotor (Oxbryta®) Medication for Sickle Cell Disease on 25th September 2024, the NHP provided a letter assist affected Sickle Cell Disorder patients.
Home
About
The MDT
Science & innovation
News & features
Events
Contact
The National Haemoglobinopathy Panel
Women’s and Children’s Academic Health - Kings College London
Becket House
1 Lambeth Palace Rd
London, SE1 7EU
Website Design by Webfactory